Lymphoid Malignancies clinical trials at UC Health

• The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

  open to eligible people ages 12-95

  This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

  at UCLA

Last updated: December 23, 2020